pharmaphorum3d
GSK's Nucala gains US use in rare autoimmune disease
GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...
pharmaphorum17d
GSK eyes nasal polyps use for Nucala after trial success
GlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation caused by nasal polyps hit its targets, bringing it into competition ...
Healio4d
Six-month asthma control score on mepolizumab predicts remission in eosinophilic asthma
Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...
Hosted on MSN1mon
FDA to review GSK’s Nucala for COPD
The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala (mepolizumab) as an add-on maintenance treatment for chronic obstructive pulmonary ...
Hosted on MSN26d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...
Medical News Today20d
Nucala administration
Nucala (mepolizumab) is a brand-name subcutaneous injection that comes in different forms. Depending on which form you’re prescribed, you or your doctor will administer the injection.
Benzinga.com29d
GSK's Sinus Disease Drug Secures Approval In China
Get Wall Street's Hottest Chart Every Morning On Friday, the China National Medical Products Administration approved GSK plc GSK Nucala (mepolizumab) as an add-on therapy with intranasal ...
Nasdaq29d
GSK’s Nucala Gains Approval in China for CRSwNP
Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval ...
Business Insider1mon
GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal ... chronic sinusitis with nasal polyps. Mepolizumab is already approved in China ...
Yahoo Finance29d
GSK’s Nucala Gains Approval in China for CRSwNP
GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...
AOL29d
GSK's Sinus Disease Drug Secures Approval In China
On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on therapy with intranasal corticosteroids for adult patients with chronic ...